搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
centerforbiosimilars
10 小时
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...
centerforbiosimilars
1 天
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...
centerforbiosimilars
3 天
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...
centerforbiosimilars
10 天
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
centerforbiosimilars
6 天
FDA Approves Imuldosa, a Biosimilar to Stelara
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
centerforbiosimilars
7 天
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...
centerforbiosimilars
13 天
The Top 5 Biosimilar Articles for the Week of September 30
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...
centerforbiosimilars
12 天
Treatment Persistence, Safety After Switching to Infliximab Biosimilars in Canadians With IBD
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...
centerforbiosimilars
9 天
Biosimilar Rituximab Safe, Effective for SLE After Switching
A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...
centerforbiosimilars
8 天
Duke Publishes Recommendations for Developing CGT Biosimilars
Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...
centerforbiosimilars
17 天
Fourth Ustekinumab Biosimilar, Otulfi, Approved in US
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
centerforbiosimilars
11 天
Biosimilars Policy Roundup for September 2024—Podcast Edition
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈